Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma.
- 2026-03
- Clinical Trial
- Neurology(R) neuroimmunology & neuroinflammation 13(2)
- Candice C Poon
- Kathleen M Hagen
- Susobhan Sarkar
- Reza Mirzaei
- Claudia Silva
- Aito Ueno
- Paula de Robles
- Gloria Roldan-Urgoiti
- V Wee Yong
- PubMed: 41632924
- DOI: 10.1212/nxi.0000000000200530
- Moderate evidence
- Clinical
Niacin treatment increases the frequencies of circulating memory T cells and natural killer cells while decreasing nonclassical monocytes.
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes
- Dose
- dose escalation